- Home
- DNUT vs PRTA Comparison
DNUT vs PRTA Comparison
Compare DNUT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- PRTA
- Stock Information
- Founded
- DNUT 1937
- PRTA 2012
- Country
- DNUT United States
- PRTA Ireland
- Employees
- DNUT N/A
- PRTA N/A
- Industry
- DNUT Food Chains
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- PRTA Health Care
- Exchange
- DNUT Nasdaq
- PRTA Nasdaq
- Market Cap
- DNUT 917.1M
- PRTA 809.8M
- IPO Year
- DNUT 2021
- PRTA N/A
- Fundamental
- Price
- DNUT $4.92
- PRTA $12.38
- Analyst Decision
- DNUT Buy
- PRTA Buy
- Analyst Count
- DNUT 8
- PRTA 9
- Target Price
- DNUT $13.13
- PRTA $54.57
- AVG Volume (30 Days)
- DNUT 3.1M
- PRTA 439.8K
- Earning Date
- DNUT 05-08-2025
- PRTA 05-07-2025
- Dividend Yield
- DNUT 2.85%
- PRTA N/A
- EPS Growth
- DNUT N/A
- PRTA N/A
- EPS
- DNUT 0.02
- PRTA N/A
- Revenue
- DNUT $1,665,397,000.00
- PRTA $135,157,000.00
- Revenue This Year
- DNUT $1.24
- PRTA N/A
- Revenue Next Year
- DNUT $12.40
- PRTA $131.75
- P/E Ratio
- DNUT $274.40
- PRTA N/A
- Revenue Growth
- DNUT N/A
- PRTA 47.92
- 52 Week Low
- DNUT $4.87
- PRTA $11.70
- 52 Week High
- DNUT $16.05
- PRTA $26.36
- Technical
- Relative Strength Index (RSI)
- DNUT 27.20
- PRTA 38.08
- Support Level
- DNUT $5.38
- PRTA $12.46
- Resistance Level
- DNUT $5.59
- PRTA $13.52
- Average True Range (ATR)
- DNUT 0.25
- PRTA 0.73
- MACD
- DNUT 0.06
- PRTA -0.08
- Stochastic Oscillator
- DNUT 5.75
- PRTA 23.24
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).